PORT WASHINGTON, N.Y. – Pall Corporation (NYSE:PLL) will present a suite of advanced filtration products to optimize laboratory processes at the 2011 Pittcon Conference and Expo. Scientists from around the world will gather at Pittcon 2011 to learn about the latest technology and instrumentation for life sciences.

The conference will take place at the Georgia World Congress Center in Atlanta, from March 13-18.

Highlights of Pall’s product showcase (Pittcon booth 2353) will include the following:

•AcroPrep™ Advance Filter Plates provide high performance membranes in an optimized filter plate configuration for diagnostic, genomic and protein applications. New sealing technology and advanced tip design result in faster, uniform filtration rates, improving well-to-well, plate-to-plate and lot-to-lot consistency.

•Pall’s new Microsep™ Advance and Macrosep® Advance Ultrafiltration Centrifugal Devices simplify many common nucleic acid and protein handling procedures, facilitating higher volumes of pure product and high recovery rates of up to 90%. Ultrafiltration reduces the amount of handling that can cause damage to samples, leaving concentrated samples ready for direct incorporation into downstream applications at critical stages in the discovery process. Pall’s microfiltration centrifugal devices are used in separation and small-scale general filtration procedures, and can be combined with chromatography resins to create a fast, efficient method for purifying proteins.

•High performance Acrodisc® PSF Syringe Filters expedite automated sample processing and clarification. The automation-certified Acrodisc filter is more retentive than standard 25 mm devices and is available with single-layered membranes or multi-layered glass fiber prefilters. Engineered for retention efficiency, Acrodisc PSF syringe filters with GHP membrane extend column life by as much as 46 times and provide two to four times the throughput of standard glass fiber prefilter devices. Also HPLC and ion chromatography certified, the Acrodisc filter is available with GHP hydrophilic polypropylene membrane for maximum chemical compatibility, fast flow rates, low protein binding, and low levels of UV-absorbing extractables.

“Pall filtration products are staples in our customers’ QC and research laboratories. Our newest products improve the efficiency and profitability of laboratory processes at all levels,” said Larry O’Connell, senior vice president global lab products.

Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Pall technologies are also used to collect and process blood components and help protect patients from hospital-acquired infections. The Company’s membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics and proteomics markets. Pall is a leading provider of separation systems, and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer, and require less energy and water to produce.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.4 billion for fiscal 2010, is an S&P 500 company with more than 10,000 employees serving customers worldwide. To see how Pall is helping enable a greener, safer, more sustainable future, visit www.pall.com/green.